Actinium Ac 225 Satoreotide Tetraxetan

**Semantic type:** Pharmacologic Substance

**Definition:** A radioconjugate consisting of satoreotide, a somatostatin receptor 2 (SSTR2) antagonist, that is linked, via the chelating agent tetraxetan, to the alpha-emitting radioisotope actinium Ac 225, with potential antineoplastic activity. Upon administration, actinium Ac 225 satoreotide tetraxetran targets and binds to SSTR2 overexpressed on many types of neuroendocrine tumor (NET) cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of alpha radiation to SSTR2-positive cells. SSTR2 is present in large numbers on NETs and their metastases, while most normal tissues express low levels of SSTRs.

**Synonyms:** - 225Ac-DOTA-JR-11 - 225Ac-Satoreotide Tetraxetan - 5Ac-SSO110 - Actinium Ac 225 SSO110 - Actinium Ac 225-DOTA-JR11 - Actinium Ac 225-labeled SSO110 - [ 225Ac]-Satoreotide Tetraxetan - [225Ac]-SSO110 - [Ac-225]-Satoreotide Tetraxetan